23-HN-38-BG(BGB-HNSCC-201):A Phase 2, Randomized, Open-label, multi-arm Study of Tislelizumab in Combination with Investigational Agents as First Line Treatment in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Grants and Contracts Details

StatusActive
Effective start/end date10/26/23 → 10/26/25

Funding

  • BeiGene USA Incorporated: $33,365.00